(Image: Screenshot of the Glooko.com website)
Glooko, the maker of a digital platform for managing diabetes and other chronic diseases, announced today a $30 million Series D funding round led by Health Catalyst Capital. Canaan Partners, Georgian, Novo Nordisk, Insulet and Mayo Clinic also played a part in the raise.
WHAT IT DOES
The Palo Alto startup's app-based platform acts as a central hub for connected monitoring devices and other disease-relevant data streams. Users, for instance, can import the data from their glucose meter or CGM. (The company claims to be compatible with 95% of all diabetes devices.)
Then they view those readings alongside their meal logs or activity data collected through third-party fitness platforms like Fitbit or Strava. Users can also review educational resources or follow care programs tracked by the app, and export all of their data for review by their doctor.